Phosphate Binder Prescription Dosing
For calcium acetate, start with 1334 mg (2 tablets of 667 mg) per meal for most patients, with sevelamer carbonate starting at 800-1600 mg three times daily with meals based on serum phosphorus levels, while aluminum hydroxide should only be used short-term (4 weeks maximum) at standard doses when phosphorus exceeds 7.0 mg/dL.
Calcium Acetate Dosing
Starting dose: 1334 mg (2 tablets of 667 mg) per meal for typical patients 1
- If switching FROM calcium acetate TO sevelamer carbonate:
- 1 tablet calcium acetate (667 mg) → 0.8 g sevelamer carbonate
- 2 tablets calcium acetate → 1.6 g sevelamer carbonate
- 3 tablets calcium acetate → 2.4 g sevelamer carbonate 2
Critical calcium limits: Total elemental calcium from binders must not exceed 1,500 mg/day, and total calcium intake (including dietary) must not exceed 2,000 mg/day 1. This is essential because excessive calcium intake increases vascular calcification risk and mortality, particularly in patients over 65 years 1, 3, 4.
Sevelamer Carbonate Dosing
Adults Not on Phosphate Binders
Serum phosphorus-based starting doses 2:
- Phosphorus >5.5 and <7.5 mg/dL: 0.8 g three times daily with meals
- Phosphorus ≥7.5 mg/dL: 1.6 g three times daily with meals
Titration: Increase by 0.8 g three times daily every 2 weeks until target phosphorus achieved 2
Typical maintenance dose: Average 7.2 g/day; maximum studied dose is 14 g/day 2
Pediatric Patients (≥6 years)
Dosing based on body surface area (BSA) 2:
- BSA ≥0.75 to <1.2 m²: Start 0.8 g three times daily; titrate by 0.4 g increments
- BSA ≥1.2 m²: Start 1.6 g three times daily; titrate by 0.8 g increments
Aluminum Hydroxide Dosing
Restricted use only: Reserve for severe hyperphosphatemia (phosphorus >7.0 mg/dL) 1
Duration: Maximum 4 weeks, single course only, then switch to alternative binders 1
Rationale: Short-term use (4 weeks) does not cause aluminum bone disease or neurotoxicity, but prolonged use carries significant morbidity risk 1. The mortality risk from severe hyperphosphatemia (>6.5-7.0 mg/dL) justifies brief aluminum use 1.
Critical contraindication: Never combine with calcium citrate—citrate dramatically increases aluminum absorption and can precipitate acute aluminum toxicity 1
Clinical Decision Algorithm
CKD Stages 3-4
- Start with calcium-based binders (calcium acetate preferred) 1
- Lower doses typically sufficient due to residual kidney function 1
- Switch to non-calcium binders if calcium >10.2 mg/dL or PTH <150 pg/mL 1
CKD Stage 5 (Dialysis)
Either calcium-based OR sevelamer carbonate acceptable as initial therapy 1
Prefer sevelamer carbonate if:
Combination therapy: Use both calcium-based and non-calcium binders if phosphorus remains >5.5 mg/dL despite monotherapy 1
Aluminum hydroxide: Only if phosphorus >7.0 mg/dL and refractory to other binders; consider increasing dialysis frequency simultaneously 1
Administration Timing
Take with meals: All phosphate binders must be taken with meals for efficacy 1
Sevelamer carbonate preparation: Mix powder in 30-60 mL water (depending on dose), stir vigorously, drink within 30 minutes 2
Drug interactions: If patient takes other medications, separate sevelamer carbonate by 1-3 hours to avoid binding interactions 5, 6
Common Pitfalls
Exceeding calcium limits: Many patients on calcium acetate/carbonate receive >1.5 g elemental calcium daily, increasing calcification risk 7. Calculate elemental calcium content carefully.
Normophosphatemia treatment: Do not start phosphate binders in patients with normal phosphorus—this may worsen vascular calcification without benefit 4
Inadequate monitoring: Check phosphorus monthly after initiation, adjust doses every 2 weeks 1
Hypercalcemia management: If calcium >10.2 mg/dL, reduce or stop calcium binders immediately and switch to sevelamer carbonate 1